Home / Markets / Industries / Health Care
Wednesday, November 18, 2009
Vivus Shares Rise on Erectile Dysfunction Drug Success
By Darryl R. Isherwood
FOXBusiness
Vivus Inc. (VVUS) shares rose Wednesday on news that its erectile dysfunction drug was effective in a late stage trial, putting the biotech firm on course to file an application with the Food and Drug Administration in 2011.
The shares were up about 3% in late afternoon trading.
Vivus Chief Executive Leland Wilson said the company’s treatment may work faster and have fewer side effects than other treatments on the market.
“Erectile dysfunction is a significant problem among more than half of all men over the age of 40,” he said, according to the Wall Street Journal. “While sales of currently available ED therapies exceed $3.8 billion a year, persistent switching by patients suggests that patients are less than satisfied with current therapies.”
The success of its ED drug comes as Vivus is planning to file a new drug application for its obesity drug after positive results in late stage tests.
Fox Business Video
-
-
Euro Debt Could Boost Gold
-
Feb 9, 2010
FOXBusiness.com LIVE
-
-
-
Health-Care Reform vs. Job Creation
-
Feb 9, 2010
Question of the Day
-
-
-
Ron Paul on Stimulus
-
Feb 9, 2010
Future of government bailouts?
-
-
-
U.S. No Longer the Space Explo...
-
Feb 9, 2010
Future of space program
-
-
-
Toyota Will Recover
-
Feb 9, 2010
Will the auto manufacturer bounce back?
-
Last 5 Stocks
- Ticker
- Company
- Price
- Change